维力医疗上半年净利润1.21亿元 业绩稳健增长

Company Performance - In the first half of 2025, the company achieved total operating revenue of 745 million yuan, a year-on-year increase of 10.19% [2] - The net profit attributable to the parent company's shareholders was 121 million yuan, reflecting a year-on-year growth of 14.17% [2] - The company's main business revenue reached 731 million yuan, with a year-on-year increase of 10.35% [2] Product Performance - Revenue from anesthesia products was 209 million yuan, a decline of 4.79% year-on-year [2] - Revenue from catheter products was 220 million yuan, an increase of 13.62% year-on-year [2] - Revenue from urology products was 134 million yuan, showing a significant growth of 43.90% year-on-year [2] - Revenue from nursing products was 92 million yuan, with a year-on-year increase of 30.28% [2] - Revenue from blood dialysis products was 40 million yuan, reflecting an 18.44% year-on-year increase [2] - Revenue from respiratory products was 27 million yuan, a decline of 38.54% year-on-year [2] Industry Outlook - The Chinese medical device market is experiencing steady growth, with the overall market size expected to increase from 729.8 billion yuan in 2020 to 941.7 billion yuan in 2024, and projected to reach 1,813.4 billion yuan by 2035 [3] - The global medical device market is also expanding, with the market size expected to grow from 456.6 billion USD in 2020 to 623 billion USD in 2024, and projected to reach 1,157.6 billion USD by 2035 [3]